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Heterotopic transplantation of pluripotent stem cells 
(PSCs) produces growths known as teratomas (Greek 
word for monstrous), which consist of a heterogeneous 
amalgamation of fetal-like tissues. Engraftment of even 
a  few  undifferentiated  cells  is  potentially  sufficient 
for teratoma formation. Such an event would have far 
reaching consequences for the future of this field. Current 
differentiation protocols produce cultures with unknown 
degrees of purity and are therefore potentially hazardous. 
We provide here a succinct overview of current methods 
and outline challenges for the removal of residual 
teratoma-initiating cells. 
Retrospective and prospective approaches for 
teratoma depletion have been the subject of significant 
investigation. Retrospective removal includes standard 
oncologic treatments of formed tumors via radiation, 
chemotherapy, and surgery [1]. To avoid the inevitable 
side effects of oncologic treatments, transplantable 
cells  have  been  modified  with  suicide  genes  prior  to 
engraftment. In this way, grafts can be ablated in the event 
of uncontrolled growth. This approach has been applied 
clinically and demonstrated efficacy in abrogating graft-
versus-host disease in patients undergoing transplantation 
of donor T-cells modified with an inducible Caspase-9 
gene [2]. Naujok et al. have adapted this approach to 
PSCs through transduction of a construct where an OCT4 
promoter controls HSV1 thymidine kinase expression, 
allowing for selective ablation of undifferentiated PSCs 
upon treatment with of Ganciclovir [3]. Unfortunately, 
these types of removal will eliminate the desired grafted 
cells along with teratoma-forming cells. 
Prospective depletion of teratoma-initiating 
cells is advantageous to retrospective removal as such 
methods prevent initial tumor formation. Two main 
strategies of prospective removal include treatment with 
agents  specifically  cytotoxic  to  undifferentiated  cells 
and  mechanical  separation.  The  first  was  extensively 
developed by the lab of Dr. Andre Choo, who produced 
the cytotoxic antibody mAb 84 which targets PODXL, 
a protein abundantly expressed by PSCs [4]. Other 
molecules such as ceramides have also been employed. 
For example, Bieberich et al. utilized the ceramide 
analogue, N-oleoyl serinol, to induce selective apoptosis 
in PSC-derived cultures [5]. 
Non-cytotoxic cell separation has emerged as a 
central approach for depletion of teratoma-initiating cells. 
This method relies on tagging undifferentiated cells either 
by inducing reporter gene expression or through reversible 
labeling of surface antigens. Labeled cells are then 
removed through fluorescence- or magnetic-activated cell 
sorting (FACS or MACS). Although tagging PSC-specific 
surface antigens is considered safer than introducing 
gene reporters [6], this goal has been difficult to achieve 
due to the lack of exclusive surface markers. To address 
this shortage, we have recently created a monoclonal 
antibody specific for the newly identified PSC antigen 
named  stage  specific  embryonic  antigen-5  (SSEA-5). 
Furthermore, we demonstrated that FACS using SSEA-
5 dramatically reduces the teratoma potential of partially 
differentiated cultures and completely abolishes this 
potential when SSEA-5 is combined with two additional 
markers [7]. As an alternative, a recent study demonstrated 
that MACS employing a lectin that binds PSC-expressed 
carbohydrates facilitates removal of undifferentiated cells 
[8].
A major advantage to utilizing surface markers 
for prospective separation is that this method relies on 
the intrinsic properties of the cells and therefore can be 
applied to all PSC lines and differentiation conditions. A 
typical protocol may entail removing cells expressing a 
tailored combination of surface markers such as SSEA-
5 and/or CD9 and/or CD90 [7]. Such a protocol may 
occur before full maturation of a culture or with the final 
cellular product. In cases where cell dissociation perturbs 
interactions required for graft’s function, post-depletion 
re-aggregation is required. We also note that antibody-
based sorting is safer than genetic modification since the 
latter has been implicated in oncogenic transformation [6]. 
In summary, we propose that prospective removal 
is superior to retrospective approaches since the latter 
may result in anatomical damage and also risks malignant 
and/or metastastic transformation. As such, retrospective 
removal should always be considered a backup rather than 
first line. We also believe that clinical utilization of PSC 
derivatives should rely on combination of prospective 
approaches to provide the highest level of safety. One 
example  is  to  utilize  PSC-specific  antibodies  for  cell 
separation followed by a subsequent cytotoxic antibody 
incubation step [4]. Ultimately, teratoma removal poises a 
significant yet surmountable challenge. With development 
of stringent removal procedures and close monitoring of 
PSC-derived grafts, we believe that such therapeutics can 
be applied effectively and safely. Oncotarget 2012; 3:  7 - 8 8 www.impactjournals.com/oncotarget
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